A phase II study of Platinum-doublet chemotherapy in combination with nivolumab as first-line treatment in subjects with unresectable, locally advanced or metastatic G3 Neuroendocrine Neoplasms (NENs) of the gastroenteropancreatic (GEP) tract or of unknown (UK) origin. (NICE-NEC study)

**PIs:**
- Dra. Rocío García Carbonero
- Dra. María del Carmen Riesco

**STUDY DESIGN**

**SCREENING**
- Metastatic or unresectable G3 NEN of GEP or UK origin
- Treatment naive
- ECOG ≤2

**INDUCTION PHASE**
- Nivolumab 360mg/IV/D1/Q3W
- Carboplatin (AUC=5) IV/D1/Q3W
- Etoposide 100mg/m²/day/IV/D1-D3/Q3W

**MAINTENANCE PHASE**
- Nivolumab 480mg/IV/Q4W

**N = 38**
- 6 cycles
- For 24 months or until PD, death or toxicity